Post on 13-Apr-2018
transcript
1
Controlled Release
Reservoir-Membrane Systems
2
Overview
n Historyn Membrane devices with constant release raten Diffusion cell experiments with first order
releasen Burst and lag effects in membrane systemsn Diffusion coefficientsn Membrane materialsn Applications of membrane systems
3
Components of membrane systems
n Mechanism: diffusion-controlledn Driving force: ?C across membranen Medium: polymer membrane or liquid-filled
poresn Resistance: function of film thickness,
diffusivity of solute in mediumn Membrane usually interfaces with biological
site. Biocompatibility may be important.
4
History of Membrane Systems
n Folkman and Long (1966 patent)n Folkman studied effect of thyroid hormone on heart
blockn Folkman needed non-inflammatory vehicle for
extended release of hormonen Long performed a photographic study of turbulence
induced by artificial Si rubber heart valvesn Long noticed that certain dyes permeated Si rubber
5
History (continued)
n Folkman and Long tested diffusion of dyes and drugs across Si tube walls.q Observed that oil-soluble, low MW (<1000) dyes
permeated membraneq Observed that water-soluble, high MW dyes did not.
n This was the beginning of a research EXPLOSION!n First CR device (late 1960s) was use of hormones
for contraception, which has now been widely studied.
6
Theory
n Fick’s First Law
n Relate Cm1 and Cm2 to surrounding concentrations
n Rewrite Flux
n Body acts as a sink (C2˜ 0)
n Constant rate can be achieved if C1 is kept constant.
−
−=−=h
CCD
dxdCm
DJ mm 12
−
−==h
CCDKJ m
12
2
22 C
CK m
m =1
11 C
CK m
m =
≅
hC
DKJ m1
membrane
C1
C2h
Cm1
Cm2
C1<Cm1the drug “prefers”the polymer
7
What if C1 is not constant?
n Common situation in diffusion cellq Drug is depleted from reservoir (1)q Drug accumulates in receiver (2)
membrane
C1
C2h
Cm1
Cm2
www.permegear.com
8
Diffusion cell: Derivation of M1(t)
n Fick’s Law
n USS Mass Balance
−
−=−=h
CCDK
dxdCm
DJ m12
( )
+−=
−
=−=
21
21
2211
11VV
AJdt
CCddt
dCA
Vdt
dCAV
J
n Combine USSMB with Fick’s Law
n Rearrange
( ) ( )
+−−=
−
2121
21 11VV
CCl
ADKdt
CCd
( )( ) dt
VVlADK
CCCCd
+−=
−−
2121
21 11
9
Diffusion cell
n Integrate with IC: C1-C2= C10-C2
0
q Apply mass balance
q Substitute
( )( ) t
VVlADK
CCCC
+−=
−−
210021 11
ln21
0121 MMM =+
222
111
VCMVCM
==
10
Diffusion cell
n Rearrange (see details)
n Differentiate to find release rate
n First Order Release Rate
( )
+
+−+
= 121
212
21
01
1 exp VVlV
tVVADKV
VVM
M
( )
+−−=
21
21
1
011 exp
VlVtVVADK
lVADKM
dtdM
11
Release profile for diffusion cell
Drug Release in Diffusion Cell
0
2
4
6
8
10
12
0 2000 4000 6000 8000 10000
time (min)
mas
s o
f dru
g in
res
ervo
ir
(mg
)
12
Data Analysis
n Diffusion Cell Experiment provides data for C1 vs t n Rearrange equation for M1
n Taking natural log of both sides results in linearizedeqn
( ) ( )
+−=−
+
21
21210
1
211 expVlV
tVVADKVV
MVVM
( ) ( )
mxby
VlVtVVADK
VVM
VVM
+=
+−+=
−
+
21
212
1
101
211 )ln(ln
13
Graphing diffusion cell data
n Experiment:q L=2.5x10-3 cmq V1=V2=3 cm3
q A = 2 cm2
q K = 1 (water-filled pores)
n Analysisn m = -0.000533s-1
n m = n Solve for Dn D=1.0 x 10-6 cm2/s
Caffeine Release through Microporous Membrane
0
2
4
6
8
10
12
0 2000 4000 6000 8000 10000
time (min)
mas
s o
f d
rug
in r
eser
voir
(m
g)
Aqueous Diffusion Coefficient of Drugs
y = -0.000533x + 1.098612
-16-14-12-10
-8
-6-4-202
0 5000 10000 15000 20000 25000 30000 35000
time (s)
log
((M
1*(V
1+V
2)/M
10-V
1)
( )
+−
21
21
VlVVVADK
14
Burst and Lag Effects
n Previous analysis was based on steady-state flux in membrane
−
−=−=h
CCD
dxdCm
DJ mm 12
membrane
C1
C2h
Cm1
Cm2
15
Burst and Lagn Lag
membrane
C1
C2
h
Cm1
Cm2
Membrane exposed to reservoir at t=0
Initially no drug in membrane
Takes time to build up SS concentration gradient
n Burstmembrane
C1
C2
h
Cm1
Cm2
Device stored before use
Initial concentration of drug in membrane = C1
Takes time for drug to desorb and achieve SS concentration gradient
16
Lag Time & Burst Effect
Equations for the amount of drug released after SS is attained in the membrane:
n Lag
n Burst
n Equations result from solving transport eqns. (Fick’s 2nd Law) for USS diffusion with relevant ICs; then taking limit as t ? 8
n These equations are for C1=const; C2=0
−=
Dl
tl
ADKCM SS
6
21
2
+=
Dl
tl
ADKCM SS
3
21
2
17
Burst and Lag Effects
lagtD/ll
ADKC
Dl
tl
ADKCM
-6intercept-x
t vsM of slope
6
Lag
2
1
21
2
=−=
=
−=
lADKC
Dl
tl
ADKCM
12
21
2
t vsM of slope
3
Burst
=
+=
The lag time is the time required for the solute to appear on the receiver side. It is also the time required to attain a SS concentration profile in the membrane
18
Effect of lag and burst
n Membrane thickness 100 micronsn D = 1 x 10 -7 cm2/sn Calculate Lag time and Burst timen Repeat for D = 1 x 10-9 cm2/s
D = 1 x 10 -7 cm2/s D = 1 x 10-9 cm2/stlag = 2.7 min tlag = 277 mintburst = 5.5 min tburst = 555 min
19
Diffusivity values for polymers
n Function of MWq Greater dependence for solute in polymers than
for solute in liquids.q For drugs with <400 MWn In water: 10-6 cm2/s<D<10-4 cm2/s
q Weak dependence on MW
n In rubbery polymer: 10-11 cm2/s<D<10-4 cm2/sq MW is somewhat important
n In glassy polymer: 10-14 cm2/s<D<10-5 cm2/sq Polymer is very stiff and rigid. Strong dependence on MW
20
Diffusion through microporousmembranesn Molecules move through
liquid-filled poresn Small molecules do not
experience hindered diffusion
n Porosity 0 < e <1n Tortuosity typically 1 < t <5
q pathlength is longer than membrane thickness
τεD
Deff =
21
Membrane materials
n Silicone (Silastic – Dow Corning)n EVA – Ethylene Vinyl Acetateq EVAc- Ethylene Vinyl Acetate copolymer
n Entrapped fluidsq Hydrogels and microporous membranes
22
Silicone membranes
n Biocompatible and steriliziblen High permeability to many steroidsn Low permeability to ionized speciesn Fick’s law is valid for many compoundsn D is on the order of 10-6
q High compared to many polymers
23
Applications of Silicone membranes
n 5 year contraceptiven Transderm Nitro patch: 0.843 mg/cm2/day
24
EVA Membrane Systems
n Advantages over siliconeq Lower permeability to non-polar compounds offers
better rate controlq Easier processing and formation of thermoplasticn Extrusion, injection molding, film casting
q Co-polymers can effect big changes in propertiesn Flexibility, permeability, strength
25
Examples of EVA Systemsn Progestasert
q Progesterone contraceptive by ALZAq Intrauterine device, 65 mcg per day for 400
daysq Silicone T-shaped tube with 35 mg drug in
Si oil
26
Examples of EVA Systems
n Ocusertq Pilocarpine glaucoma
treatment system by ALZAq Thin, flexible “contacts” behind
eyelidq Use once a week; replaces
drops 4 times per dayq Releases 20 or 40 mcg per
hourq Contains 5-11 mg pilocarpineq Sterilized by irradiation
1. Clear EVA membrane2. Opaque white sealing
ring3. Pilocarpine reservoir4. Clear EVA membrane
q Oval shape, 6 mm x 13 mm x 0.5 mm
q Thin EVA membranes 100 microns thick
27
Hydrogel systems
n Hydrophilic monomers that make cross-linked networks which hold waterq Great ease of synthesisq Wide range of propertiesq D depends on cross-linking agent and water
content
28
Applications of hydrogels membrane systemsn Fluoride salts in the moughq 0.2 – 1.0 mg/day for 6 months
n Narcotic agonist – cyclazocineq Prevents opiate effect and is used in rehabilitation
n Anticancer pouches for direct placement on tumors
29
Applications of microporous membranes
n Microporous Membranes – used in many biomedical applicationsq Blood oxygenation, dialysis, wound dressings, drug delivery
n Drug Delivery Applicationsq Transderm Scop® (scopolamine) —Introduced in 1981 for motion-sickness. Microporous
polypropylene membrane. (Alza-Ciba Geigy)
q Transderm-Nitro® (nitroglycerin) — For angina patients. Alternative to the brief effects of sublingual nitroglycerin and the messiness of nitroglycerin ointment. Microporous EVA membrane. (Alza-Ciba Geigy)
q Catapres-TTS® (clonidine) — Once-a week patch for hypertension replaces up to four daily oral doses. Uses microporous polypropylene membrane. (Alza-Boehringer/Ingelheim)
q Estraderm® (estradiol) —Twice-weekly, convenient estrogen replacement therapy. Avoids first pass and therefore uses only a fraction of the drug used in the oral therapy. Uses microporouspolypropylene membrane. (Alze-Ciba Geigy)
q Duragesic® (fentanyl) —Introduced in 1991 for management of chronic pain via opioid analgesia. Uses microporous polyethylene membrane. (Alza)
q NicoDerm® CQ® (nicotine)—smoking-cessation aid in multiple dosage strengths offering maximum control of the drug delivery rate. Uses microporous polypropylene membrane. (Alza-GSK)
q Testoderm® and Testoderm® —Introduced in 1994 and 1998, respectively, for hormone replacement therapy in men with a deficiency or absence of testosterone. Microporous EVAcmembrane. (Alza-Lederle)
30
ALZA’s Transderm ScopRemovable strip
Rate controlling microporousmembrane with highly permeable liquid in pores
Foil backing, protective and impermeable
Adhesive gel layer with priming dose
Reservoir with solid drug in highly permeable matrix
n Controlled release form maintains low conc of drug, reduces side effects
n 2.5 cm2 arean 200 mcg priming dosen 10 mcg/h for 72 h steady state delivery
31
Diffusion Cell Equations
n Derivation of M1(t)
32
Burst and Lag effects
Ref. Kydonieus, A. Treatise on Controlled Drug Delivery